ArticleChemMedChem2026
Breaking Down Barriers: CorA Effectively Targets Staphylococcal Biofilms in Vitro and in Vivo.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Activity of Corallopyronin A Against ESKAPEE Pathogens: Potential and Translational Implications.Antibiotics (Basel, Switzerland) · 2026Article
- Breaking Down Barriers: CorA Effectively Targets Staphylococcal Biofilms in Vitro and in Vivo.ChemMedChem · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Biofilm-associated infections caused by Staphylococcus aureus (S. aureus) remain notoriously difficult to treat due to their pronounced tolerance to most antibiotics. Here, we evaluated the antibiofilm efficacy of the natural product antibiotic corallopyronin A (CorA) across a panel of strains, including clinically relevant strains differing in their biofilm-forming capacities and antibiotic resistance profiles. CorA is an alpha-pyrone antibiotic produced by Corallococcus coralloides. It targets the switch region of the bacterial DNA-dependent RNA polymerase, thereby blocking transcription initiation at a site distinct from the rifampicin-binding pocket, and displays potent activity against staphylococci, including MRSA and rifampicin-resistant S. aureus. In vitro, CorA eradicated and inhibited biofilm formation, outperforming the biofilm-active antibiotics dalbavancin and rifampicin both in optical density measurements and in microscopic analyses. Importantly, CorA had activity against rifampicin-resistant strains in these assays. In a murine foreign body infection model with S. aureus SA113, CorA treatment resulted in a > 4-log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.